财务分析作业年报(英文版)课件.ppt
- 【下载声明】
1. 本站全部试题类文档,若标题没写含答案,则无答案;标题注明含答案的文档,主观题也可能无答案。请谨慎下单,一旦售出,不予退换。
2. 本站全部PPT文档均不含视频和音频,PPT中出现的音频或视频标识(或文字)仅表示流程,实际无音频或视频文件。请谨慎下单,一旦售出,不予退换。
3. 本页资料《财务分析作业年报(英文版)课件.ppt》由用户(三亚风情)主动上传,其收益全归该用户。163文库仅提供信息存储空间,仅对该用户上传内容的表现方式做保护处理,对上传内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!
4. 请根据预览情况,自愿下载本文。本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
5. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007及以上版本和PDF阅读器,压缩文件请下载最新的WinRAR软件解压。
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 财务 分析 作业 年报 英文 课件
- 资源描述:
-
1、Financial analysis course work Guangzhou Baiyunshan Pharmaceutical Co.,Ltd.2010 Annual Report Analysis International Institute of Accounting 0803 Team members Analysis Outline n1.Introduction n2.Common ratio analysis n3.Related Ratio Analysis n4.Comparative Analysis of competitors n5.Conclusions 1.I
2、ntroduction(1)Basic information of company nChinese Company Name:Guangzhou Baiyunshan Pharmaceutical Co.,Ltd.nName in English:Guangzhou Baiyunshan Pharmaceutical Co.,Ltd.nChinese abbreviation of the company:Baiyunshan PharmaceuticalnCompany abbreviation:BYSnLegal representative:Mr.Xie BinnBoard Secr
3、etary:Mr.Qiao YongnAddress:Baiyun District,Guangzhou City,Guangdong Province,and the street with 88 Yunxiang RoadnPhone:020-87062599 Fax:020-87,063,699nE-mail:nSecurities Affairs Representative:Miss Gao YanzhunAddress:Baiyun District,Guangzhou City,Guangdong Province,and the street with 88 Yunxiang
4、RoadnPhone:020-87062599 Fax:020-87,063,699nE-mail: 1.Introduction(2)Company Business Description Guangzhou Baiyunshan Pharmaceutical Co.,Ltd.Established in 1973,1992,Guangzhou Municipal Peoples Government of 11 menstrual approved by the General Pharmaceutical Factory,Guangzhou Baiyun Mountain,such a
5、s the establishment of five joint-stock companies through the restructuring of enterprises,in November 1993 as the first batch of Guangzhou City Listed companies listed on the Shenzhen Stock Exchange,now has total share capital of 469 million.Sales volume in 2007 reached 3.61 billion yuan in 2008 sa
6、les volume of over 4 billion yuan.?company focused on the pharmaceutical industry,the business includes the production and management of a variety of dosage forms of Chinese and Western medicine,chemical raw materials,external use,childrens medicine,health medicine and other drugs.After years of dev
7、elopment,under the White Cloud Mountain a total of 12 member companies,have all passed the national GMP,GSP certification,Guangzhou Baiyun Mountain Innovation Centre Chemical Pharmaceutical Engineering Technology Center in Guangdong Province.?the company over the years to brand building,establishing
8、 the first pharmaceutical preparations in the country one of the brand,its brand awareness and reputation among consumers in the country has a strong influence.2006 White Cloud Mountain trademark was identified as well-known trademarks in China in 2007,was identified as focus on training and develop
9、ment of exports of Guangdong Province Famous Brand title brand value in 2008 was assessed to be 10.52 billion yuan.Business:development,production,sales of Chinese and Western medicine,chemical raw materials,external use,childrens medicine,health medicine.Operation of commercial and material supply
10、and marketing.Operating various types of goods and technology import and export business(except for national limit and prohibition).Management and feed processing and the three to fill a business.Production of two types of clinical testing of the instruments and diagnostic reagents.1.IntroductionMai
11、n operations by industry Sub-industry or product Revenue Operating costs Gross margin(%)Operating income over last year Operating cost over last year Gross margin over last year Chemicals,pharmaceutical raw materials manufacturing industry 43,678.35 39,405.26 9.78%26.74%30.63%-2.69%Chemical preparat
12、ions manufacturing 193,184.22 116,208.43 39.85%22.67%15.09%+3.97%Chinese herbal medicines and traditional Chinese medicine processing industry 82,040.35 54,892.24 33.09%6.48%17.72%-6.39%Other Pharmaceutical Manufacturing 614.93 624.58-1.57%-12.17%-31.42%+28.51%Pharmaceutical commodity circulation 5,
13、684.95 2,449.00 56.92%5.29%9.46%-1.64%Total 325,202.80 213,579.51 34.32%18.22%18.06%+0.09%(3)2010 annual operating results Unit:million 一、公司介绍(3)annual operating results in 2010 Unit:millionMain business by product Amoxicillin 22,265.91 11,471.46 48.48%-3.41%6.01%+1.43%Qingkailing 27,359.76 13,684.5
14、2 49.98%25.72%34.64%-3.32%Yili Keteling 20,778.76 18872.159.18%5.49%9.76%-3.53%Cephalosporin sulfide injection 26,499.15 13781.0147.99%29.23%37.18%-3.02%Cefixime 14,685.91 4273.9970.90%23.27%20.45%+0.69%Ceftriaxone API 12,737.83 12920.93-1.44%54.41%59.96%-3.52%Cefuroxime 10,073.58 9716.133.55%13.71%
15、16.86%-2.60%(3)2010 annual main business regions Unit:millionRegion Revenue Operating income over last year South China 153171.5715.95%East China 40378.8130.20%North China 39083.7439.35%Northeast 11390.0611.15%Southwest 28585.8134.39%Northwest 4986.6223.38%Central China 47606.19-1.58%Total 325202.81
16、8.22%二、共同比分析Comparison of accounting data calendar Unit:Yuan201020092008Total operating income 3,316,861,029.18 2,795,105,546.58 2,635,870,540.72 Gross profit 257,089,118.33 117,617,343.45 115,966,090.00 Net profit attributable to shareholders of listed companies 204,736,590.14 107,765,675.43 76,407
17、,343.62 Deduction attributable to shareholders of the Companys net non-recurring gains and losses 163,981,242.93 49,316,518.08 38,644,489,063.00 Cash flow from operating activities Net 327,214,424.47 300,141,134.16 83,532,831.99 The end of 2010The end of 2009 The end of 2008 Total assets 3,055,310,5
18、11.65 2,945,054,275.46 2,814,309,427.45 Therefore attributable to shareholders of listed companies the rights and interests 1,106,532,618.04 912,534,940.30 804,974,766.55 Equity(shares)469,053,689.00 469,053,689.00 469,053,689.00 2.Common ratio analysisLongitudinal analysis of the common ratio Balan
19、ce Sheet Assets December 31,2010 December 31,2009 December 31,2008 Total current assets 50.05%49.67%45.76%Total non-current assets 49.95%50.33%54.24%Total assets 100.00%100.00%100.00%Total liabilities and equity December 31,2010 December 31,2009 December 31,2008 Total current liabilities 56.90%62.29
20、%63.55%Total non-current liabilities 4.97%4.83%6.03%Total Liabilities 61.87%67.13%69.58%Total equity 38.13%32.87%30.42%Total liabilities and equity 100.00%100.00%100.00%2.Common ratio analysisLongitudinal analysis of the common ratio Income Statement Income Statement December 31,2010 December 31,200
21、9 December 31,2008 Revenue 100.00%100.00%100.00%Operating costs 65.00%65.41%67.40%Business tax and surcharges 0.73%0.90%0.83%Selling expenses 15.46%16.84%15.16%Management fees 11.25%12.07%11.31%Finance costs 1.57%2.28%3.62%Impairment of assets 0.10%0.63%0.58%Operating profit 7.19%3.03%2.77%Gross pro
22、fit 7.75%4.21%4.40%Net profit 6.60%4.34%3.19%2.Common ratio analysisnSummary of longitudinal analysis of the common ratio Company for more rational use of funds in the future development of the debt the company is facing down,the company increased mobility,improved ability to repay the debt,the ente
23、rprises reputation is more secure.Company attaches importance to the use of new technologies,improve the internal management more streamlined,better customer service.Net income increased to increase the effectiveness of the company,the investors have more confidence in the stability.2.Common ratio a
24、nalysisAssets December 31,2010December 31,2009December 31,2008Total current assets 118.72%113.56%100%Total non-current assets 99.99%97.12%100%Total assets 108.56%104.65%100%Total liabilities and equity December 31,2010December 31,2009December 31,2008Total current liabilities 97.19%102.57%100%Total n
25、on-current liabilities 89.57%83.86%100%Total Liabilities 96.53%100.95%100%Total equity 136.09%113.10%100%Total liabilities and equity 108.56%104.65%100%Common ratio of horizontal Balance Sheet 2.Common ratio analysisCommon ratio of horizontal Income Statement Income Statement December 31,2010Decembe
展开阅读全文